24 Jan 17

CEROVIVE , a neuroprotectant with free radical scavenging properties, is a drug under development by AstraZeneca and licensed from Renovis,for more inquiries:media inquiries: Edel McCaffrey:+44 207 304 5034 Steve Brown, Tel:+44 207 304 5033investors: Mina Blair, Tel:+44 207 304 5084 Jonathan Hunt, Tel:+44 207 304 5087Notes to editors: AstraZeneca a major international healthcare business in the research, development, manufacture and marketing of prescription pharmaceuticals and is employed in the health services. It is one of of the world’s leading pharmaceutical companies with sales of more than $ 18800000000 and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products www.penegra100mg.com/reviews.html . AstraZeneca is listed in the Dow Jones Sustainability Index as well the FTSE4Good Index.

The SAINT trials for CEROVIVE are being conducted in 40 countries in 400 centers , the evaluated evaluated in acute ischemic stroke patients. The safety of patients studies studies evaluated continuously.


GlaxoSmithKline – one of the most leading research-based pharmaceutical and healthcare companies – committed to improving the quality of human life by connecting people to do more, are feeling better and live longer.

Grietens ‘ study was carried out on behalf of the Policy – Oriented Primary Education Research Program Committee of the NWO. Creative.